Eighth Annual AONN+ Conference Abstracts

Category I: Community Outreach/Prevention, Eighth Annual AONN+ Conference Abstracts

Community Outreach: Inside a Community Tumor Board. Prevention, Treatment, and Survivorship in Breast Cancer

Melanie Lynch, MD, FACS; Sharon Lieb Inzetta, RN, MS, CBCN, CN-BN; Heidi Eve-Cahoon, MSN, RN, CNP, CBCN; Laura Musarra, BS, MBA
Summa Health, Akron, OH 

Background: Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both [ Read More ]

Category I: Community Outreach/Prevention, Eighth Annual AONN+ Conference Abstracts

Early Outcomes of a Pancreatic Cancer Familial Risk Assessment Program

Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG; Nora J. Barrett, BSN, RN, OCN, ONN-CG; Kristi C. Garrison, MS, CHES, CHW, OPN-CG; Kristi M. Griffith, MSN, RN, CHPN
Baylor Charles A. Sammons Cancer Center at Dallas, Dallas, TX 

Background: Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is [ Read More ]

Category I: Community Outreach/Prevention, Eighth Annual AONN+ Conference Abstracts

Lung Cancer Screenings – Winning Battles in the Lung Cancer War

Amy M. Norton, RN, MSN, ONN-CG (T); Dawn M. Deacon, RN, BSN, OCN, ONN-CG; Wendy L. Brooks, RN, ONN-CG (T)
Sarah Cannon Cancer Institute – HCA Midwest Health, Kansas City, MO 

Background: According to Morgan,1 “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.” A projected “222,500 [ Read More ]

Category I: Community Outreach/Prevention, Eighth Annual AONN+ Conference Abstracts

Real-Time Breast Cancer Risk Assessment at Screening Mammography

Kathy Albano, RN, BSN, CN-BN
Beekley Center for Breast Health & Wellness
Bristol Hospital, Bristol, CT
 

Background: Each woman’s risk of developing breast cancer is different and depends on her lifestyle, family health history, and other factors. The American Cancer Society considers women who have a [ Read More ]

Category II: Care Coordination/Care Transitions, Eighth Annual AONN+ Conference Abstracts

Benefits of Implementing an Automated Workflow Cancer Conference Platform

Lijo Simpson, MD; Anju Mathew, MBA; Doris Jones, MSN, RN, OCN; Kim Gullion, MSN, RN, OCN;
George Miranda
DeKalb Medical, Atlanta, GA 

Background: The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists. Benefits of MCCs include coordination, direction for complicated [ Read More ]

Category II: Care Coordination/Care Transitions, Eighth Annual AONN+ Conference Abstracts

Creating a Pediatric Cancer Immunotherapy Nurse Navigator Role: Developing Complex Care Coordination Processes

Claire White, BSN, RN, CPHON
The Children’s Hospital of Philadelphia
Philadelphia, PA
 

Background: Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell [ Read More ]

Category II: Care Coordination/Care Transitions, Eighth Annual AONN+ Conference Abstracts

Improving Compliance and Patient Outcomes with a Presurgery Gynecologic Oncology Educational Video and Survey

Antoinette Solnik, RN, BSN, ONN-CG, RYT-200; Allison Steinberg, MSN, MPH, RN, OCN
The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital
Washington, DC
 

Background: The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually. After creating an initial written postoperative educational tool, [ Read More ]

Category II: Care Coordination/Care Transitions, Eighth Annual AONN+ Conference Abstracts

The Oncology Nurse Navigator’s Role in Enhancing the Multidisciplinary Cancer Conference at a Community Cancer Hospital

Heather Hannon, MSN, RN, CBCN, OCN, ANP-BC
Sarah Cannon Cancer Institute at Johnston Willis Hospital
Richmond, VA
 

Background: The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care. MCCs offer multiple benefits, including increased use of [ Read More ]

Category III: Patient Advocacy/Patient Empowerment, Eighth Annual AONN+ Conference Abstracts

A Patient/Provider Discussion Tool for Chronic Myeloid Leukemia

Claire Saxton, MBA1; Heather Hollen, MS1; Jenny Karubian, MA2; Alexandra Zaleta, PhD2
1Cancer Support Community, Washington, DC
2Cancer Support Community, Research and Training Institute
Philadelphia, PA
 

Background: The Cancer Support Community (CSC) has designed a patient/provider discussion tool for patients with chronic myeloid leukemia (CML). The main goal of the tool is to help patients and [ Read More ]

Category III: Patient Advocacy/Patient Empowerment, Eighth Annual AONN+ Conference Abstracts

Carcinoid Syndrome Impact Survey: Evaluation of the Burden of Illness and the Gap Between Patient and Oncologist Perceptions

Grace Goldstein, MA1; Kathleen Evans, MBA2; Arpan Shah, PharmD, MBA3; Pablo Lapuerta, MD3
1Carcinoid Cancer Foundation, White Plains, NY
2Healogix, LLC, Horsham, PA
3Lexicon Pharmaceuticals, Inc, The Woodlands, TX
 

Background: Patients with advanced neuroendocrine tumors may develop carcinoid syndrome, a rare condition characterized by debilitating symptoms, including diarrhea, flushing, and valvular heart damage, that can greatly affect patient social [ Read More ]

Category III: Patient Advocacy/Patient Empowerment, Eighth Annual AONN+ Conference Abstracts

Structured Exercise Prescription Program: Targeting Monolingual Spanish-Speaking Patients to Improve Impairments

Lisa Ross, BS, ACSM/ACS Certified Cancer Exercise Trainer; Tracy Mazour, RN, MSN, OCN; Stephanie Mamantov, ACSM/ACS Certified Exercise Trainer; Emily Berry, MSPH; Aurelio Rodriguez; Keith Argenbright, MD
Moncrief Cancer Institute/UT Southwestern
Fort Worth, TX
 

Background: Exercise is a multipurpose tool that can be used to help cancer survivors improve their quality of life (QOL) across the cancer continuum. Cancer and its treatments result in [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

A Quantitative and Qualitative Quality-of-Life Evaluation of a Large Navigation Team

JaLisa Boyd, MS, BSN, RN; Emily Gentry, RN, BSN, OCN; Katie Narvarte, LMSW
Medical City Healthcare/Sarah Cannon Cancer Institute 

Background: Sarah Cannon Cancer Institute, the Oncology Service line for Medical City Healthcare in the Dallas/Fort Worth, Texas area, has a team of 13 disease-suite oncology nurse navigators and 2 [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

Efficacy of the Breast Cancer Navigator Role in Reducing Distress in Newly Diagnosed Breast Cancer Patients: A Pilot Study

Patricia Johnson, BS, RN, OCN, CBCN1; Anne Bongiorno, PhD, APHN-BC, CNE2
1University of Vermont Health Network – CVPH
2State University of New York at Plattsburgh
 

Background: Each year at a rural northeastern hospital, approximately 100 women and men are diagnosed with breast cancer. For most patients, this is a first diagnosis with cancer. Patients receive [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

Examining the Mutual Benefits of a Peer Support Program to Facilitate Adaptation Among Women Affected by Breast/Ovarian Cancer: The Sharsheret Experience

Adina Fleischmann, LSW; Elana Silber, MBA; Melissa Rosen, MA
Sharsheret, Teaneck, NJ  

Background: Frank Riessman’s Helper Theory (1965) posits that peer support networks can be powerful tools to extend care delivery—benefiting both the giver and receiver of informal care. Studies continue to [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

Quality of Life of Caregivers to Those Living with Chronic Myelogenous Leukemia

Ian Kudel, PhD1; Susan Gabriel, MS2; Erika Szabo, MPH, MSPharm2; Jifang Zhou, MD, MPH3; Ashutosh K. Pathak, MD, PhD, MBA, FRCP(Edin)2; Boxiong Tang, MD, PhD2; Nicola Brooksbank, BSN, RN, OCN4; Ryan Liebert, MS1
1Kantar Health, New York, NY
2Teva Pharmaceuticals, Frazer, PA
3University of Illinois at Chicago, College of Pharmacy, Chicago, IL
4Duke University Hospital, Durham, NC
 

Background: Research has consistently found that caregivers for people with cancer report distress; however, it is not clear whether recent improvements in the treatment of chronic myelogenous leukemia (CML) have [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

Screening for Supportive Oncology Patient Concerns, Analyzing Impact and Opportunities to Improve Spiritual Questions Affecting Navigation to Spiritual Resources

Stephanie Merce Boecher, RN, OCN, MSN, BSN, BA1; Julia R. Trosman, PhD, MBA2; Carol Newsom, RN3; Rosa Berardi4; Javier Macias, BA5; Dirk Labuschagne, MDiv6; Harry Miranda-Ocasio, PsyD6; James Gerhart, PhD7; Teresa Lillis, PhD7; Pam Khosla, MD8; Catherine Cassingham, MSW, LSW8; Anne Bowman, MBA, CHES9; Ana Gordon, AM, LCSW10
1Advocate Health Care
2The Center for Business Models in Healthcare
3Mercy Hospital and Medical Center
4The Coleman Foundation
5The Leukemia & Lymphoma Society
6John H. Stroger Jr. Hospital of Cook County
7Rush University Medical Center
8Mount Sinai Hospital
9UnityPoint Health – Peoria
10University of Illinois Hospital & Health Sciences
 

Background: The Institute of Medicine (IOM) 2013 report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) Standard 3.2 requires distress screening and indicated action. [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

The Emotional Journey Among Caregivers of Patients with Leukemia: The Caregivers’ Perspective Based on Social Media Listening

Susan Gabriel, MS1; Kerri Phillips, MBA2; Erika Szabo, MPH, MSPharm1; Mary Ann Slater, MBA3; Jifang Zhou, MD, MPH4; Ashutosh K. Pathak, MD, PhD, MBA, FRCP(Edin)1; Nicola Brooksbank, BSN, RN, OCN5; Boxiong Tang, MD, PhD1; Lulu K. Lee, PhD6
1Teva Pharmaceuticals, Frazer, PA
2Kantar Health, New York, NY
3Kantar Health, London, UK
4University of Illinois at Chicago, College of Pharmacy, Chicago, IL
5Duke University Hospital, Durham, NC
6Kantar Health, San Mateo, CA
 

Background: The burden of cancer has largely focused on the patient. However, caregivers also experience considerable burden. Objectives: This study’s aim was to use social media posts to better understand [ Read More ]

Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

The Therapy Dog Will See You Now

Margaret Rummel, BSN, MHA, OCN, NE-BC; Laura Galindez, MSW, LSW; Heather Sheaffer, DSW, LCSW
Abramson Cancer Center, Philadelphia, PA 

Background: Animal Assisted Therapy (AAT) is a supportive therapy that is currently underutilized in the outpatient oncology setting. AAT has been used to provide support for cancer patients, but a [ Read More ]

Category V: Professional Roles and Responsibilities, Eighth Annual AONN+ Conference Abstracts

Educational Needs Related to Nursing Skill Level and Awareness of Navigating the Complexities of the Cancer Care Continuum

Sharon Gentry, RN, MSN, CBCN, AOCN, ONN-CG1; Lillie Shockney, RN, BS, MAS, ONN-CG2; Margaret V. Clark, MSc, RN, RRT-NPS, CMPP3
1Breast Nurse Navigator, Novant Health Derrick L. Davis Cancer Center, Winston-Salem, NC
2Professor of Surgery, Professor of Breast Cancer, Johns Hopkins Hospital School of Medicine, Baltimore, MD
3Clark Medical Writing, North Chesterfield, VA
 

Background: The Academy of Oncology Nurse & Patient Navigators conducted a 1.5-day live conference April 27-29, 2017, in Phoenix, AZ. Objectives: To provide education, promote discussion, and identify strategies to [ Read More ]

Category V: Professional Roles and Responsibilities, Eighth Annual AONN+ Conference Abstracts

Integrating Metrics and Role Delineation into a Navigation Program for Quality Improvement

Sandra Miller, MHSM, RN, NE-BC1; Carolyn Allsen, BSN, RN, OCN, ONN-CG2; Sylvia Brown, MS, RN, OCN, CNL, ONN-CG3; Krystie Fenton, BSN, RN, OCN4; Carol Kirton, BSN, RN, OCN5; Angela Sisk, MSN, RN, OCN, AHN-BC6; Deidra Teoh, MSN, RN, OCN, ONN-CG7
1Oncology Service Line; 2Memorial Hermann – The Woodlands; 3Memorial Hermann – The Medical Center; 4Memorial Hermann – Southeast & Pearland; 5Memorial Hermann – Northeast; 6Memorial Hermann – Greater Heights; 7Memorial Hermann – Southwest & Sugar Land 

Background: Since the inception of the oncology nurse navigator (ONN) program at Memorial Hermann Hospital System (MHHS) in 2009, the role of the ONN was vastly misunderstood, and the overall [ Read More ]

Category V: Professional Roles and Responsibilities, Eighth Annual AONN+ Conference Abstracts

Navigating the Course from Diagnosis to Survivorship: The Implementation of the Nurse Navigator Role in a Pediatric Oncology Cancer Center

Peggy Townsend, MSN, RN, CPON; Jackie Gonzalez, DNP, MBA, ARNP, NEA-BC, FAAN; Lilliam Rimblas, RN, BSN, CPHON
Nicklaus Children’s Hospital, Miami, FL 

Background: Navigation is defined as the “guiding force promoting the timely movement of the patient through a complex system of care.” Evidence from leading adult cancer centers has shown that [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Benefits of a Multidisciplinary Clinic Operations Workgroup as a Forum for Navigator Coordinators and Quality Improvement

Alyssa Pauls, RN, BSN, OCN; Cynthia Smith, RN, BSN, MA, OCN; Kathleen Sevedge, RN, MA, AOCN; Laura Beaupre, RN, BSN, OCN, CN-BN; Maritza Chicas, RN, BSN, OCN; Jeanne Kenna, RN, OCN; Angela Miller, RN, MEd, OCN; Raizalie Roman, RN, BSN, OCN; Jane Zubia, RN, OCN, CN-BN
Lehigh Valley Health Network Cancer Institute, Allentown, PA  

Background: Multidisciplinary care is recognized as a sign of quality cancer care according to several organizations, including the American Society of Clinical Oncology, the Institute of Medicine, the National Cancer [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Effectiveness of the Managing Cancer at Work Program

Marie Borsellino, RN, MSN, ONN-CG
Johns Hopkins, Baltimore, MD 

Background: The number of cancer survivors is increasing because of advances in detection and treatment. More than 15.5 million Americans with a history of cancer were alive as of January [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Helping Breast Cancer Patients Manage Care Transitions Through Patient and Navigator Use of 4R Care Plans, 4R = Right Information/Care/
Patient/Time

Julia R. Trosman, PhD, MBA1,2; Jennifer Stein, RN3; Valerie Nelson, MD, MBA4; Jennifer Tepper, MSN, APN, CBCN, CNS4; Cathy Spagnoli, MSHA, RN, CBCN, CN-BN, ONN-CG5; William J. Gradishar, MD, FASCO, FACP6; Claudia B. Perez, DO7; Mikele Bunce, MPH, PhD8; Wayne Pan, MD, PhD8; Liliana Mendoza, RN7; Alma Sotelo, CN-BA7; Swati Kulkarni, MD1; Lynn Galuska Elsen, RN, BSN, IBCLC3; Christine Weldon, MBA2
1Northwestern University
2The Center for Business Models in Healthcare
3Northwestern Medicine
4Northwestern Medicine Lake Forest
5Northwestern Lake Forest Hospital
6Mercy Hospital and Medical Center
7Genentech
 

Background: Transitions in care require well-managed timing and sequencing of events across specialties. The IOM 2011 and 2013 reports recommend a written care plan at cancer diagnosis to enable cross-discipline [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Impact of a Workplace Educational Webinar Series Focused on the Needs of Employees and Their Family Members Living with a Cancer Diagnosis

Marie Borsellino, RN, MSN, ONN-CG
Johns Hopkins, Baltimore, MD 

Background: As people with a history of cancer are living longer and surviving their cancer, today it is estimated that there are 14 million cancer survivors in the United States. [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Impact on Caregivers of Patients (Pts) with Myeloproliferative Neoplasms (MPNs) in the United States: Results from the Living with MPNs (LWMPN) Survey

Dilan Paranagama, PhD1; Shreekant Parasuraman, BPharm, PhD1; Andrew Bai, MS1; Jingbo Yu, PhD1; Ruben Mesa, MD, FACP2
1Incyte Corporation, Wilmington, DE
2Mayo Clinic, Scottsdale, AZ
 

Background: The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general [ Read More ]

Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts

Virtual Oncology Navigation Program: Patient Hotline Access for Self-Advocacy

Joyce Schaffer, RN, MSN, AOCNS; Susan G. Haag, PhD, MS; Janet Eriksen, BSN, BA, RN; Mary Jo Baldwin, AA; Erkut Borazanci, MD; Dan Von Hoff, MD
HonorHealth Research Institute, Scottsdale, AZ 

Background: Patient navigation has been shown to improve patient engagement and participation in clinical trials1-3 and reduce barriers to cancer care.4,5 Despite growing evidence of value, oncology patient navigation is [ Read More ]

Category VII: Operations Management, Organizational Development, Health Economics, Eighth Annual AONN+ Conference Abstracts

Can Transparency of Individual Navigation Performance Improve Overall Navigation Program’s Operational and Quality Metrics?

Kendra Nelms, MHA, RN, OCN
Sarah Cannon, San Antonio, TX 

Background: Sarah Cannon’s San Antonio market was seeking a way to effectively improve key quality and operational navigation metrics on their monthly Navigation Market Scorecard. The market scorecard was reflective [ Read More ]

Category VIII: Survivorship and End of Life, Eighth Annual AONN+ Conference Abstracts

If We Build It Will They Come?

Sandra Miller, MHSM, RN, NE-BC1; Carolyn Allsen, BSN, RN, OCN, ONN-CG2; Sylvia Brown, MS, RN, OCN, CNL, ONN-CG3; Krystie Fenton, BSN, RN, OCN4; Carol Kirton, BSN, RN, OCN5; Angela Sisk, MSN, RN, OCN, AHN-BC6; Deidra Teoh, MSN, RN, OCN, ONN-CG7
1Oncology Service Line; 2Memorial Hermann – The Woodlands; 3Memorial Hermann – The Medical Center; 4Memorial Hermann – Southeast & Pearland; 5Memorial Hermann – Northeast; 6Memorial Hermann – Greater Heights; 7Memorial Hermann – Southwest & Sugar Land 

Background: The American Cancer Society acknowledged an estimated 1,688,780 new cancer diagnoses by the end of 2017. A survivor is defined as, “any person with a history of cancer, from [ Read More ]

Category VIII: Survivorship and End of Life, Eighth Annual AONN+ Conference Abstracts

Impact of Perceived Cognitive Impairment on Work-Related Outcomes in Breast Cancer Survivors

Jill Dodson, LSW, LMHC, LMFT, CCM; Charlotte Howard, MSN, RN, CBCN; Diane Von Ah, PhD, RN, FAAN; Adele Nielsen, BSN, RN; Sarah Dutkevitch, RN, OCN; Susan Storey, PhD, RN, AOCNS
Indiana University Health North Hospital, Carmel, IN 

Significance: Work is central for most adults in the United States, including women with breast cancer. More than 90% of breast cancer survivors (BCS) in the United States return to [ Read More ]

Category VIII: Survivorship and End of Life, Eighth Annual AONN+ Conference Abstracts

The Healthy Forks Survivorship Series…Fighting Cancer One Fork at a Time

Jennifer Fitzgibbon, MS, RDN, CSO, CDN 

Background: Cancer patients must juggle doctor appointments; combat treatment side effects, while trying to maintain a sense of normalcy; and handle financial struggles. Stony Brook is a state-funded healthcare institution; [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Adverse Event Management During Treatment with Everolimus plus Exemestane for Postmenopausal Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer (ABC)

Jan Hronek; Lindsay Shelby
Sarah Cannon Research Institute, Nashville, TN 

Background: The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Biomarker Testing in Metastatic Non–Small Cell Lung Cancer: Process Gaps and Best Practices Reported by Nurse Navigators and Nurse Practitioners

Marc Chioda, PharmD1; Ahsan Jamil, PharmD1; Sukriti Kaushal, BS2; Joanne C. Ryan, PhD, RN1
1Pfizer, Inc; 2Atrium Staffing 

Objectives: This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps. Background: [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Efficacy and Safety of Ribociclib for the Treatment of Advanced Breast Cancer: A Review of Subgroup Analyses from the Phase 3 Trial MONALEESA-2

Andrea Watson, RN, BSN, OCN
Saint Luke’s Koontz Center for Advanced Breast Cancer, Kansas City, MO 

Background: Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). Ribociclib is an orally bioavailable inhibitor of cyclin-dependent [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Evidence-Based Statistics on Complete Prevention and Rapid Sustained Elimination of Chemoradiation Mucositis by ProThelial—97% Reduction in Mucositis

Ricky W. McCullough, MD, MSc
MMI Translational Medicine Clinic and Research Center, Storrs, CT 

Background: Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Frequency of Mutations in Multigene Panel Testing of 324 Ovarian and/or Endometrial Cancer Patients

Lilian Servais, MS, LCGC; Anjali Zimmer, PhD; Jeroen van den Akker, PhD; Will McFadden, PhD;
Alicia Y. Zhou, PhD
Color Genomics, Burlingame, CA 

Background: Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.1 Inherited germline mutations in genes such as BRCA1 and BRCA2 have been identified in [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Patient-Reported Symptoms Reduce Health-Related Quality of Life Among Patients Undergoing Treatment for Metastatic Cancer

Dana Drzayich Antol, MS1; Adrianne W. Casebeer, PhD, MPP, MS1; Sari Hopson, PhD, MSPH1; Raya Khoury, MPH2; Aparna Parikh, MD2; Alisha Stein, RN-BC, MSN, OCN2; Todd Michael, PharmD, RPh2; Stephen Stemkowski, PhD, MHA1; Mikele Bunce, PhD, MPH2
1Comprehensive Health Insights, Humana, Louisville, KY; 2Genentech, San Francisco, CA 

Background: Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life. Objectives: This [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Pooled Analysis of Safety with Extended 3-Year Follow-up Across Combination Dabrafenib and Trametinib (D+T) Phase 3 Trials

Jean-Jacques Grob, MD, PhD1; Keith T. Flaherty, MD2; Georgina V. Long, MD, PhD3; Paul Nathan, MD4; Dirk Schadendorf, MD, PhD5; Antoni Ribas, MD, PhD6; Caroline Robert, MD7; Stephen Lane, MS8; Carmen Mak, PhD8; Bijoyesh Mookerjee, MD8; Michael A. Davies, MD, PhD9
1Aix-Marseille University, Marseille, France; 2Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA; 3Melanoma Institute of Australia and The University of Sydney, Sydney, NSW, Australia; 4Mount Vernon Cancer Centre, Northwood, UK; 5University Hospital of Essen, Essen, Germany; 6UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA; 7Gustave Roussy Comprehensive Cancer Center, Villejuif, Paris-Sud, France; 8Novartis Pharmaceuticals Corporation, East Hanover, NJ; 9The University of Texas MD Anderson Cancer Center, Houston, TX 

Background: Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant mel­anoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Single-Agent Ibrutinib in Patients with Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia: The 5-Year Experience

Fan Ny, NP; Jillian Settlemire, RN; Ying Luan, PhD; Alvina D. Chu, MD; Tony Lin; Steven E. Coutre, MD; John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH 

Background: Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

The Chimeric Antigen Receptor T-Cell Treatment Journey: Patient and Nursing Education for Managing the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel for the Treatment of Aggressive, Refractory Non-Hodgkin Lymphomas

Kathleen McDermott, RN, BSN, OCN, BMTCN1; Amy Patterson, RN2; Nicole Kahle, RN2; Alix Beaupierre, RN, BSN, OCN2; Maritza C. Alencar, DNP, ARNP-BC, BMTCN3
1Dana-Farber Cancer Institute, Boston, MA; 2Moffitt Cancer Center, Tampa, FL; 3Sylvester Comprehensive Cancer Center, Miami, FL 

Background: Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells. ZUMA-1 (NCT02348216) evaluated the anti-CD19 CAR T-cell therapy, [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Treatment Options for Premenopausal Women with Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (ABC)

Jill Schwartz Gomez, RN; Mary Lynn Breslin, RN, BSN, OCN
MD Anderson Cancer Center, Houston, TX 

Background: Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.1 Younger patients often experience aggressive disease and are [ Read More ]